Avid Bioservices Inc (CDMO)

[biopharm]

Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma

Published April 2017

Bingbing Dai, David Roife, Ya'an Kang, Joy Gumin, Mayrim V. Rios Perez, Xinqun Li, Michael Pratt, Rolf A. Brekken, Juan Fueyo-Margareto, Frederick F. Lang, and Jason B. Fleming...
...

Another PS Targeting drug....in collaborations with Merck

I thought some assumed there was no interest in collaborations with PS Targeting and all false, we see Merck all over the place ..

https://www.dnatrix.com/pipeline/

I guess Merck is very lucky to have Ronin Hedge Group split up the BOD and again very lucky to have a complete new BOD not go with an open competitive bid for better terms than what Oncologie offered

Now Merck gets to deal with Oncologie and save money ...I guess CEO Roger Lias was picked for a reason

These new BODs could just say Ronin Hedge Group was wrong in planting the seed to say drop the IP assets, that Merck wanted all along